tradingkey.logo
tradingkey.logo
検索

ImmuCell Corp

ICCC
ウォッチリストに追加
10.290USD
-0.710-6.45%
終値 07/02, 13:00ET15分遅れの株価
93.09M時価総額
損失額直近12ヶ月PER

詳細情報 ImmuCell Corp 企業名

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corpの企業情報

企業コードICCC
会社名ImmuCell Corp
上場日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)
従業員数69
証券種類Ordinary Share
決算期末May 01
本社所在地56 Evergreen Drive
都市PORTLAND
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号04103
電話番号12078782770
ウェブサイトhttps://immucell.com/
企業コードICCC
上場日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)

ImmuCell Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

よくある質問

ImmuCell Corpの上位5名の株主は誰ですか?

ImmuCell Corpの上位5名の株主は以下のとおりです。Mr. Michael F. Brigham

ImmuCell Corp(ICCC)の株式を保有している機関の数はいくつですか?

2026Q1時点で、ImmuCell Corpの株式を保有している機関は48社あり、保有株式の総市場価値は約2.16Mで、全体の23.86%を占めています。2025Q4と比較して、機関の持ち株は228934.00増加しています。

ImmuCell Corpの最大の収益源は何ですか?

2026Q1において、First Defense® product line部門がImmuCell Corpにとって最大の収益を生み出しており、その金額は27.45Mで、全収益の99.29%を占めています。